Piramal Pharma (NSE:PPLPHARMA) Change In Receivables : ₹0 Mil (TTM As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Piramal Pharma Change In Receivables?

Piramal Pharma's change in receivables for the quarter that ended in Mar. 2024 was ₹0 Mil. It means Piramal Pharma's Accounts Receivable stayed the same from Dec. 2023 to Mar. 2024 .

Piramal Pharma's change in receivables for the fiscal year that ended in Mar. 2024 was ₹-3,914 Mil. It means Piramal Pharma's Accounts Receivable increased by ₹3,914 Mil from Mar. 2023 to Mar. 2024 .

Piramal Pharma's Accounts Receivable for the quarter that ended in Mar. 2024 was ₹21,344 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Piramal Pharma's Days Sales Outstanding for the three months ended in Mar. 2024 was 76.31.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Piramal Pharma's liquidation value for the three months ended in Mar. 2024 was ₹-40,685 Mil.

Piramal Pharma Change In Receivables Historical Data

The historical data trend for Piramal Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Piramal Pharma Change In Receivables Chart

Piramal Pharma Annual Data

Trend

Mar21

Mar22

Mar23

Mar24

Change In Receivables

-2,865.20

-1,851.70

892.60

-3,913.90

Piramal Pharma Quarterly Data
	Mar21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Change In Receivables	Get a 7-Day Free Trial							-	-	-	-	-

Piramal Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0 Mil.

Piramal Pharma (NSE:PPLPHARMA) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Piramal Pharma's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	21344.3	/	25523.6	*	91
=	76.31

2. In Ben Graham's calculation of liquidation value, Piramal Pharma's accounts receivable are only considered to be worth 75% of book value:

Piramal Pharma's liquidation value for the quarter that ended in Mar. 2024 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	6431.4	-	74004.4	+	0.75 * 21344.3	+	0.5 * 21758.8
=	-40,685

Piramal Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Piramal Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Piramal Pharma (NSE:PPLPHARMA) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Piramal Pharma Ltd (NSE:PPLPHARMA) » Definitions » Change In Receivables

Traded in Other Exchanges

543635:India

Address

Piramal Ananta, Agastya Corporate Park, Opposite Fire Brigade, Kamani Junction, LBS Marg, Kurla (West), Mumbai, MH, IND, 400070

Website

https://www.piramal.com

Piramal Pharma Ltd offers a portfolio of differentiated products and services through end-to-end manufacturing capabilities across 15 global facilities and a global distribution network in over 100 countries. It includes integrated contract development and manufacturing organization business, complex hospital generics business, and India consumer healthcare business, selling over-the-counter products in India.

Piramal Pharma (NSE:PPLPHARMA) Headlines

No Headlines